AI Engines For more Details: Perplexity Kagi Labs You
Vaginal Health: Lactobacillus crispatus plays a crucial role in maintaining vaginal health by producing lactic acid and other antimicrobial substances that create an acidic environment in the vagina. This acidic environment helps inhibit the growth of harmful bacteria and yeast, reducing the risk of vaginal infections such as bacterial vaginosis (BV), yeast infections, and urinary tract infections (UTIs).
Prevention of Bacterial Vaginosis (BV): Lactobacillus crispatus is particularly important for preventing bacterial vaginosis, a condition characterized by an overgrowth of harmful bacteria in the vagina. By producing lactic acid, L. crispatus helps maintain the acidic pH of the vagina, which inhibits the growth of BV-associated bacteria such as Gardnerella vaginalis.
Urinary Tract Health: Some research suggests that Lactobacillus crispatus may play a role in preventing urinary tract infections (UTIs) by colonizing the vagina and preventing the ascent of uropathogenic bacteria into the urinary tract. By maintaining a healthy vaginal microbiota, L. crispatus may help reduce the risk of recurrent UTIs, especially in women prone to these infections.
Sexual Health: Lactobacillus crispatus contributes to overall sexual health by promoting a balanced vaginal microbiota. Imbalances in vaginal microbiota composition can increase the risk of sexually transmitted infections (STIs) and other reproductive health issues. By maintaining a healthy vaginal environment, L. crispatus may help reduce the risk of STIs and support overall sexual well-being.
Pregnancy Health: A healthy vaginal microbiota, dominated by Lactobacillus crispatus, is important during pregnancy to reduce the risk of complications such as preterm birth and miscarriage. L. crispatus helps create an environment that is conducive to a healthy pregnancy by preventing infections and promoting a balanced immune response in the vaginal mucosa.
Gastrointestinal Health: Although Lactobacillus crispatus primarily colonizes the vaginal tract, some research suggests that it may have potential benefits for gastrointestinal health. Studies have shown that certain strains of L. crispatus can survive passage through the gastrointestinal tract and may exert probiotic effects, such as supporting immune function and promoting gut barrier integrity.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.9 | 0.9 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.2 | 0.4 | -1 |
| Allergy to milk products | 0.3 | -0.3 | |
| Alzheimer's disease | 0.4 | 0.3 | 0.33 |
| Ankylosing spondylitis | 0.5 | 0.5 | |
| Anorexia Nervosa | 0.2 | 0.2 | |
| Asthma | 0.3 | -0.3 | |
| Atherosclerosis | 0.2 | -0.2 | |
| Atrial fibrillation | 0.2 | 0.2 | 0 |
| Autism | 0.7 | 0.7 | 0 |
| Bipolar Disorder | 0.2 | 0.2 | |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Carcinoma | 0.3 | 0.3 | 0 |
| Celiac Disease | 0.3 | -0.3 | |
| Chronic Fatigue Syndrome | 0.4 | 0.4 | |
| Colorectal Cancer | 0.7 | 0.7 | |
| COVID-19 | 0.5 | 0.2 | 1.5 |
| Crohn's Disease | 0.5 | 0.4 | 0.25 |
| Depression | 1.4 | 0.9 | 0.56 |
| Eczema | 0.3 | 0.3 | 0 |
| Endometriosis | 1 | 0.5 | 1 |
| Epilepsy | 0.7 | 0.7 | |
| Fibromyalgia | 0.2 | 0.2 | |
| Functional constipation / chronic idiopathic constipation | 0.2 | 0.2 | |
| gallstone disease (gsd) | 0.2 | -0.2 | |
| Generalized anxiety disorder | 0.3 | -0.3 | |
| giant cell arteritis | 0.3 | 0.3 | |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 0.3 | 0.5 | -0.67 |
| Hashimoto's thyroiditis | 0.2 | 0.2 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.3 | -0.5 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| Hyperlipidemia (High Blood Fats) | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.2 | 0.2 | 0 |
| IgA nephropathy (IgAN) | 0.2 | -0.2 | |
| Inflammatory Bowel Disease | 0.2 | -0.2 | |
| Irritable Bowel Syndrome | 0.5 | 0.2 | 1.5 |
| Liver Cirrhosis | 0.3 | 0.2 | 0.5 |
| Long COVID | 0.4 | 0.9 | -1.25 |
| Low bone mineral density | 0.2 | -0.2 | |
| ME/CFS with IBS | 0.2 | 0.2 | |
| Metabolic Syndrome | 0.9 | 0.5 | 0.8 |
| Mood Disorders | 1.6 | 1.2 | 0.33 |
| Multiple Sclerosis | 0.8 | 0.8 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.5 | -1.5 | |
| Obesity | 1 | 0.3 | 2.33 |
| obsessive-compulsive disorder | 0.2 | 0.2 | |
| Osteoporosis | 0.7 | -0.7 | |
| Parkinson's Disease | 1.1 | 1.1 | |
| Polycystic ovary syndrome | 0.7 | -0.7 | |
| Psoriasis | 0.2 | 0.2 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.4 | 0.2 | 1 |
| Schizophrenia | 0.4 | 0.8 | -1 |
| sensorineural hearing loss | 0.5 | 0.5 | |
| Sjögren syndrome | 0.2 | 0.2 | 0 |
| Sleep Apnea | 0.7 | -0.7 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
| Stress / posttraumatic stress disorder | 0.2 | 0.2 | |
| Systemic Lupus Erythematosus | 0.5 | -0.5 | |
| Type 2 Diabetes | 0.8 | 0.5 | 0.6 |
| Ulcerative colitis | 0.4 | 0.4 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.